InstalabHSV 2 % Inhibition
Should you take a HSV 2 % Inhibition test?
This test is most useful if any of these apply to you.
About HSV 2 % Inhibition
A positive herpes antibody screen can affect relationships and treatment decisions. HSV-2 inhibition testing helps determine whether that screening result reflects antibodies specific to herpes simplex virus type 2. Some reference laboratories run it automatically as a confirmation step after a reactive screen. It does not have the standing of Western blot. CDC guidelines name Western blot and one other assay, which is no longer sold, as the confirmatory options, and inhibition testing is not among them. An individual inhibition result can also be inconclusive or disagree with another method. Quest Diagnostics, CDC guidance
What the Percentage Measures
Antibodies are proteins your immune system makes in response to infection. IgG antibodies can remain detectable long after the first symptoms. Published HSV-2 inhibition assays examine whether these antibodies specifically bind to a viral protein called glycoprotein G2. In the studied assays, separate portions of serum are mixed with material from HSV-2 and HSV-1 before the remaining antibody binding is measured. The percentage expresses how much binding is blocked by HSV-2 material relative to the comparison condition. This helps distinguish type-specific binding from nonspecific reactions. Hogrefe et al.
The specimen and laboratory platform for this catalog entry are unspecified. The studies discussed here used serum obtained from blood samples, so their performance estimates apply to those particular assays. The lab's written interpretation is needed alongside the percentage.
This percentage describes antibody specificity. It does not measure the amount of virus, your protection against infection, or how infectious you are. There is no established percentage to aim for through treatment. Quest Diagnostics
Why Screens Need Confirmation
False-positive HSV-2 screens are a substantial problem, especially when the screening signal is weak. In a study of people who sought confirmation at a specialist clinic, about 60% of low-positive screening results did not confirm by Western blot. That was a selected population, so the figure isn't your personal probability of a false positive. The study compared a screening antibody assay with Western blot; it did not measure the accuracy of inhibition testing. Agyemang et al.
Stronger screening signals are more likely to confirm, but false positives also occur among strongly reactive samples. A study comparing two screening platforms found that nearly all of a selected group of discordant samples failed a combined confirmation assessment. Agreement between screening tests and confirmation depends on the platforms and population being tested. Prince et al., 2019, Prince et al., 2022
| Who Was Studied | What Was Found | What the Finding Establishes |
|---|---|---|
| 21,006 serum samples with positive HSV-2 screens at a US laboratory | Inhibition was negative in 1.33% and indeterminate in about 0.2%; most samples confirmed. | These are confirmation frequencies for that laboratory series. Without an independent reference test, they do not establish diagnostic accuracy. Shates et al. |
| 781 serum samples from African cohorts | The screening assay was reported as 100% sensitive and 96% specific when inhibition testing was used as the reference. | Those figures describe the screening assay relative to inhibition. They are not sensitivity and specificity estimates for inhibition itself. Hogrefe et al. |
| 120 young men in Kisumu, Kenya, with different subsets receiving each assay | Inhibition classified a larger share as positive than Western blot. | The disagreement remained unresolved. It cannot establish that every additional inhibition-positive result represented an infection missed by Western blot. Smith et al. |
The Kenyan comparison also illustrates why results from different settings can't be pooled into one accuracy claim. The tests were performed on partly different subsets, and the investigators could not definitively resolve every disagreement. Early antibody development and differences in antibody recognition were possible explanations. Smith et al.
If You Already Get Cold Sores
HSV-1 antibodies can complicate inhibition testing. In the large US laboratory series, indeterminate results were associated with higher HSV-1 antibody signals. Most, but not all, indeterminate samples were HSV-1 positive. HSV-1 positivity was not significantly more common among inhibition-negative samples than among confirmed positives. These findings do not establish that HSV-1 causes every unclear result. Shates et al.
HSV-1 commonly causes cold sores, but it also causes genital herpes. An HSV-1 antibody result cannot establish where that infection is located. A history of cold sores therefore doesn't settle whether a separate HSV-2 screen is true or false. CDC guidance
What a Confirmed Result Means
Confirmed HSV-2 antibodies support a diagnosis of HSV-2 infection, which usually involves the genital or anal area. The percentage cannot date the infection or identify who transmitted it. CDC guidance, CDC overview
Genital herpes is lifelong, though many people have mild or unrecognized symptoms. Outbreaks may become less frequent over time, and transmission can occur without visible sores. Those facts concern infection itself; the inhibition percentage does not predict your outbreak pattern or the likelihood of transmission during a particular encounter. CDC overview
HIV Risk
HSV-2 infection is associated with a substantially higher risk of acquiring HIV after exposure. The studies establishing this relationship compared people with and without HSV-2 infection using antibody-status tests. They did not grade HIV risk by inhibition percentage, so a higher percentage cannot be translated into greater HIV risk. Wald and Link
In people living with HIV, observational research has linked HSV-2 coinfection to altered immune responses and greater immune activation. A systematic review found no consistent evidence that HSV-2 antibody positivity itself accelerates HIV disease progression. These findings concern coinfection and viral activity, not the numerical inhibition result. Sheth et al., Tan et al.
Other Disease Associations
HSV-2 can cause meningitis. In a Danish cohort of 205 adults with diagnosed HSV-2 meningitis, women predominated and many participants had not fully recovered by hospital discharge. This was a study of people already ill with nervous-system infection. It does not estimate the chance of meningitis from a positive antibody result or an inhibition percentage. Jakobsen et al.
A review of published cases of herpes-related brain and blood-vessel disease found that blocked-vessel strokes were more often associated with HSV-2, while bleeding was more often associated with HSV-1. Case reports of these unusual complications cannot establish stroke risk for otherwise well people with HSV-2 antibodies. Hauer et al.
A separate meta-analysis associated HSV infection with artery disease, but the included studies were observational and did not establish causation. They assessed infection status rather than inhibition percentages. These findings do not validate this result as a cardiovascular risk marker. Wu et al.
When Results Can Be Misleading
- Early infection: antibodies take time to become detectable. Research comparing serum screening assays with Western blot found different detection times across methods; those timings are not a validated timeline for this inhibition percentage. Ashley-Morrow et al.
- Interference from HSV-1 antibodies: some samples react in a way that prevents the lab from determining whether binding is specific to HSV-2. Shates et al.
- Insufficient reactivity on repeat testing: some laboratories repeat the screen as part of confirmation. If that repeat is negative or equivocal, a percentage may not be calculable. This differs from an indeterminate result caused by HSV-1 interference. Quest Diagnostics
- Differences between assays: results depend on the laboratory procedure and the population in which it was evaluated. A percentage from one assay should not be treated as interchangeable with another laboratory's percentage or a screening index. Smith et al.
False negatives can also occur before confirmation is considered. In a small study of people with recurrent genital herpes confirmed by viral DNA testing of sores, individual antibody assays missed some established infections. Those were screening assays, not inhibition tests. An inhibition step performed only after a positive screen cannot correct a negative screen that never reaches confirmation. Van Rooijen et al.